Myeloma cells in lab, mice killed with nanoparticle-delivered RNA
Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in…
Marisa Wexler, MS, senior science writer — 
Articles by Marisa Wexler
FDA puts CART-ddBCMA Phase 2 trial on hold after patient’s death
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite…
Carvykti outperforms standard care as earlier line of therapy: Analysis
Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines…
Sarclisa plus Kyprolis found to stop cancer for nearly 3 years in trial
Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost…
Dramatic gains in survival seen in myeloma since early 2000s: Analysis
Survival outcomes for people with multiple myeloma have improved substantially over the last two decades, likely due to the availability of new, more effective…
FDA joins EU and Japan in deciding if Abecma may treat RRMM earlier
The U.S. Food and Drug Administration (FDA) has agreed to review an application that, if approved, would allow the cell therapy Abecma (idecabtagene…
CAR T-cell therapy, CB-011, on FDA fast track for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by…
New mouse models may accelerate multiple myeloma research
More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a…
Fatty acid-binding proteins may be potential target for myeloma
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new…
FDA Asked to Approve Talquetamab for Hard-to-treat Multiple Myeloma
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory…
